Top

Published in:

01-08-2021 | Diabetes | Review

Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis

Authors: Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile

Published in: Advances in Therapy | Issue 8/2021

Abstract

Obstructive sleep apnoea (OSA) is characterized by frequent apnoea episodes during sleep due to upper airway obstruction. The present review summarizes current knowledge on inter-relationships between OSA and type 2 diabetes mellitus (T2DM) and suggests the former as a possible target for sodium-glucose co-transporter-2 inhibitors (SGLT-2i). Based on pathophysiological mechanisms underlying OSA onset and renal SGLT-2 effects, we suggest that SGLT-2i indications might expand beyond current ones, including glucose, lipids, uric acid, blood pressure, and body weight control as well as chronic heart failure and kidney disease prevention.

Somers VK, White DP, Amin R, American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, American Heart Association Stroke Council; American Heart Association Council on Cardiovascular Nursing, American College of Cardiology Foundation, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118(10):1080–111. https://doi.org/10.1161/CIRCULATIONAHA.107.189375.CrossRefPubMed

Epstein LJ, Kristo D, Strollo PJ Jr, et al. Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5(3):263–76.CrossRefPubMed

Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387–94. https://doi.org/10.1378/chest.14-0970.CrossRefPubMed

Shaw JE, Punjabi NM, Wilding JP, Alberti KG, Zimmet PZ, International Diabetes Federation Taskforce on Epidemiology and Prevention. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract. 2008;81(1):2–12. https://doi.org/10.1016/j.diabres.2008.04.025.CrossRefPubMed

American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.

Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479–504. https://doi.org/10.5664/jcsm.6506.CrossRefPubMedPubMedCentral

Malhotra RK, Kirsch DB, Kristo DA, American Academy of Sleep Medicine Board of Directors, et al. Polysomnography for obstructive sleep apnea should include arousal-based scoring: an American Academy of sleep medicine position statement. J Clin Sleep Med. 2018;14(7):1245–7. https://doi.org/10.5664/jcsm.723.CrossRefPubMedPubMedCentral

Mannarino MR, Di Filippo F, Pirro M. Obstructive sleep apnea syndrome. Eur J Intern Med. 2012;23(7):586–93. https://doi.org/10.1016/j.ejim.2012.05.013.CrossRefPubMed

De Backer W. Obstructive sleep apnea/hypopnea syndrome. Panminerva Med. 2013;55(2):191–5.PubMed

10.

Lee W, Nagubadi S, Kryger MH, Mokhlesi B. Epidemiology of obstructive sleep apnea: a population-based perspective. Expert Rev Respir Med. 2008;2(3):349–64. https://doi.org/10.1586/17476348.2.3.349.CrossRefPubMedPubMedCentral

11.

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of sleep medicine task force. Sleep. 1999;22(5):667–89.

12.

Greco C, Spallone V. Obstructive sleep apnoea syndrome and diabetes. Fortuitous association or interaction? Curr Diabetes Rev. 2015;12(2):129–55. https://doi.org/10.2174/1573399811666150319112611.CrossRefPubMed

13.

Ancoli-Israel S, Gehrman P, Kripke DF, et al. Long-term follow-up of sleep disordered breathing in older adults. Sleep Med. 2001;2(6):511–6. https://doi.org/10.1016/s1389-9457(00)00096-4.CrossRefPubMed

14.

Durán J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med. 2001;163(3 Pt 1):685–9. https://doi.org/10.1164/ajrccm.163.3.2005065.CrossRefPubMed

15.

Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17):1230–5. https://doi.org/10.1056/NEJM199304293281704.CrossRefPubMed

16.

Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997;20:705–6.CrossRefPubMed

17.

Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. 2015;3(4):310–8. https://doi.org/10.1016/S2213-2600(15)00043-0.CrossRefPubMedPubMedCentral

18.

Arnardottir ES, Bjornsdottir E, Olafsdottir KA, Benediktsdottir B, Gislason T. Obstructive sleep apnoea in the general population: highly prevalent but minimal symptoms. Eur Respir J. 2016;47(1):194–202. https://doi.org/10.1183/13993003.01148-2015.CrossRefPubMed

19.

Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006–14. https://doi.org/10.1093/aje/kws342.CrossRefPubMedPubMedCentral

20.

Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004;291(16):2013–6. https://doi.org/10.1001/jama.291.16.2013.CrossRefPubMed

21.

Vijayan VK. Morbidities associated with obstructive sleep apnea. Expert Rev Respir Med. 2012;6(5):557–66. https://doi.org/10.1586/ers.12.44.CrossRefPubMed

22.

Young T, Palta M, Dempsey J, Peppard PE, Nieto FJ, Hla KM. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin sleep cohort study. WMJ. 2009;108:246–9.PubMedPubMedCentral

23.

Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31:1071–8.CrossRefPubMedPubMedCentral

24.

Assoumou HG, Gaspoz JM, Sforza E, et al. Obstructive sleep apnea and the metabolic syndrome in an elderly healthy population: the SYNAPSE cohort. Sleep Breath. 2012;16:895–902. https://doi.org/10.1007/s11325-011-0593-y.CrossRefPubMed

25.

Foster GD, Sanders MH, Millman R, Sleep AHEAD Research Group, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32:1017–9. https://doi.org/10.2337/dc08-1776.CrossRefPubMedPubMedCentral

26.

Fredheim JM, Rollheim J, Omland T, et al. Type 2 diabetes and pre diabetes are associated with obstructive sleep apnea in extremely obese subjects: a cross-sectional study. Cardiovasc Diabetol. 2011;10:84. https://doi.org/10.1186/1475-2840-10-84.CrossRefPubMedPubMedCentral

27.

Resnick HE, Redline S, Shahar E, Sleep Heart Health Study, et al. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care. 2003;26:702–9. https://doi.org/10.2337/diacare.26.3.702.CrossRefPubMed

28.

Laaban JP, Daenen S, Léger D, et al. Prevalence and predictive factors of sleep apnoea syndrome in type 2 diabetic patients. Diabetes Metab. 2009;35:372–7. https://doi.org/10.1016/j.diabet.2009.03.007.CrossRefPubMed

29.

Lecube A, Sampol G, Lloberes P, et al. Diabetes is an independent risk factor for severe nocturnal hypoxemia in obese patients. A case–control study. PLoS ONE. 2009;4:e4692. https://doi.org/10.1371/journal.pone.0004692.CrossRefPubMedPubMedCentral

30.

Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med. 2010;181:507–13. https://doi.org/10.1164/rccm.200909-1423OC.CrossRefPubMed

31.

Lam DC, Lui MM, Lam JC, Ong LH, Lam KS, Ip MS. Prevalence and recognition of obstructive sleep apnea in Chinese patients with type 2 diabetes mellitus. Chest. 2010;138:1101–7. https://doi.org/10.1378/chest.10-0596.CrossRefPubMed

32.

Einhorn D, Stewart DA, Erman MK, Gordon N, Philis-Tsimikas A, Casal E. Prevalence of sleep apnea in a population of adults with type 2 diabetes mellitus. Endocr Pract. 2007;13:355–62. https://doi.org/10.4158/EP.13.4.355.CrossRefPubMed

33.

Kendzerska T, Gershon AS, Hawker G, Tomlinson G, Leung RS. Obstructive sleep apnea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med. 2014;190(2):218–25. https://doi.org/10.1164/rccm.201312-2209OC.CrossRefPubMed

34.

Nagayoshi M, Punjabi NM, Selvin E, et al. Obstructive sleep apnea and incident type 2 diabetes. Sleep Med. 2016;25:156–61. https://doi.org/10.1016/j.sleep.2016.05.009.CrossRefPubMedPubMedCentral

35.

Subramanian A, Adderley NJ, Tracy A, et al. Risk of incident obstructive sleep apnea among patients with type 2 diabetes. Diabetes Care. 2019;42(5):954–63. https://doi.org/10.2337/dc18-2004.CrossRefPubMed

36.

Arnardottir ES, Mackiewicz M, Gislason T, Teff KL, Pack AI. Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep. 2009;32(4):447–70. https://doi.org/10.1093/sleep/32.4.447.CrossRefPubMedPubMedCentral

37.

Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand. 2003;177(3):385–90. https://doi.org/10.1046/j.1365-201X.2003.01091.x.CrossRefPubMed

38.

Guyon A, Balbo M, Morselli LL, et al. Adverse effects of two nights of sleep restriction on the hypothalamic-pituitary-adrenal axis in healthy men. J Clin Endocrinol Metab. 2014;99(8):2861–8. https://doi.org/10.1210/jc.2013-4254.CrossRefPubMedPubMedCentral

39.

Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol (1985). 2005;99(5):2008–19. https://doi.org/10.1152/japplphysiol.00660.2005.CrossRef

40.

Mansukhani MP, Kara T, Caples SM, Somers VK. Chemoreflexes, sleep apnea, and sympathetic dysregulation. Curr Hypertens Rep. 2014;16(9):476. https://doi.org/10.1007/s11906-014-0476-2.CrossRefPubMedPubMedCentral

41.

Trombetta IC, Maki-Nunes C, Toschi-Dias E, et al. Obstructive sleep apnea is associated with increased chemoreflex sensitivity in patients with metabolic syndrome. Sleep. 2013;36(1):41–9. https://doi.org/10.5665/sleep.2298.CrossRefPubMedPubMedCentral

42.

Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol (1985). 1989;67(5):2101–6. https://doi.org/10.1152/jappl.1989.67.5.2101.CrossRef

43.

Somers VK, Mark AL, Abboud FM. Interaction of baroreceptor and chemoreceptor reflex control of sympathetic nerve activity in normal humans. J Clin Invest. 1991;87(6):1953–7. https://doi.org/10.1172/JCI115221.CrossRefPubMedPubMedCentral

44.

Fagard RH. Dipping pattern of nocturnal blood pressure in patients with hypertension. Expert Rev Cardiovasc Ther. 2009;7(6):599–605. https://doi.org/10.1586/erc.09.35.CrossRefPubMed

45.

Harris CD. Neurophysiology of sleep and wakefulness. Respir Care Clin N Am. 2005;11(4):567–86. https://doi.org/10.1016/j.rcc.2005.08.001.CrossRefPubMed

46.

Carlson JT, Hedner JA, Sellgren J, Elam M, Wallin BG. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med. 1996;154(5):1490–6. https://doi.org/10.1164/ajrccm.154.5.8912770.CrossRefPubMed

47.

Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep. 2003;26(1):15–9. https://doi.org/10.1093/sleep/26.1.15.CrossRefPubMed

48.

Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest. 1993;103(6):1763–8. https://doi.org/10.1378/chest.103.6.1763.CrossRefPubMed

49.

Usui K, Bradley TD, Spaak J, et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Cardiol. 2005;45(12):2008–11. https://doi.org/10.1016/j.jacc.2004.12.080.CrossRefPubMed

50.

Imadojemu VA, Mawji Z, Kunselman A, Gray KS, Hogeman CS, Leuenberger UA. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest. 2007;131:1406–13. https://doi.org/10.1378/chest.06-2580.CrossRefPubMed

51.

Bonsignore MR, Parati G, Insalaco G, et al. Continuous positive airway pressure treatment improves baroreflex control of heart rate during sleep in severe obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2002;166(3):279–86. https://doi.org/10.1164/rccm.2107117.CrossRefPubMed

52.

Noda A, Nakata S, Koike Y, et al. Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. Hypertens Res. 2007;30(8):669–76. https://doi.org/10.1291/hypres.30.669.CrossRefPubMed

53.

Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108(25):3097–101. https://doi.org/10.1161/01.CIR.0000103123.66264.FE.CrossRefPubMed

54.

Spallone V. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab J. 2019;43(1):3–30. https://doi.org/10.4093/dmj.2018.0259.CrossRefPubMed

55.

Ziegler D, Strom A, Kupriyanova Y, GDS Group, et al. Association of lower cardiovagal tone and baroreflex sensitivity with higher liver fat content early in type 2 diabetes. J Clin Endocrinol Metab. 2018;103(3):1130–8. https://doi.org/10.1210/jc.2017-02294.CrossRefPubMed

56.

Ziegler D, Strom A, Bönhof G, GDS Group, et al. Differential associations of lower cardiac vagal tone with insulin resistance and insulin secretion in recently diagnosed type 1 and type 2 diabetes. Metabolism. 2018;79:1–9. https://doi.org/10.1016/j.metabol.2017.10.013.CrossRefPubMed

57.

Zoppini G, Cacciatori V, Raimondo D, et al. Prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study (VNDS). Diabetes Care. 2015;38(8):1487–93. https://doi.org/10.2337/dc15-0081.CrossRefPubMed

58.

Hube F, Lietz U, Igel M, et al. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm Metab Res. 1996;28(12):690–3. https://doi.org/10.1055/s-2007-979879.CrossRefPubMed

59.

Shen J, Tanida M, Niijima A, Nagai K. In vivo effects of leptin on autonomic nerve activity and lipolysis in rats. Neurosci Lett. 2007;416(2):193–7. https://doi.org/10.1016/j.neulet.2007.02.003.CrossRefPubMed

60.

Caron A, Lee S, Elmquist JK, Gautron L. Leptin and brain-adipose crosstalks. Nat Rev Neurosci. 2018;19(3):153–65. https://doi.org/10.1038/nrn.2018.7.CrossRefPubMedPubMedCentral

61.

Santos-Alvarez J, Goberna R, Sánchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol. 1999;194(1):6–11. https://doi.org/10.1006/cimm.1999.1490.CrossRefPubMed

62.

Han C, Wu W, Ale A, Kim MS, Cai D. Central Leptin and Tumor Necrosis Factor-α (TNFα) in Diurnal Control of Blood Pressure and Hypertension. J Biol Chem. 2016;291(29):15131–42. https://doi.org/10.1074/jbc.M116.730408.CrossRefPubMedPubMedCentral

63.

Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305(6):R566–81. https://doi.org/10.1152/ajpregu.00180.2013.CrossRefPubMedPubMedCentral

64.

Allison MA, Ix JH, Morgan C, et al. Higher leptin is associated with hypertension: the multi-ethnic study of atherosclerosis. J Hum Hypertens. 2013;27(10):617–22. https://doi.org/10.1038/jhh.2013.24.CrossRefPubMedPubMedCentral

65.

Pan W, Kastin AJ. Leptin: a biomarker for sleep disorders? Sleep Med Rev. 2014;18(3):283–90. https://doi.org/10.1016/j.smrv.2013.07.003.CrossRefPubMed

66.

Berger S, Polotsky VY. Leptin and leptin resistance in the pathogenesis of obstructive sleep apnea: a possible link to oxidative stress and cardiovascular complications. Oxid Med Cell Longev. 2018;2018:5137947. https://doi.org/10.1155/2018/5137947.CrossRefPubMedPubMedCentral

67.

Lüdemann P, Dziewas R, Sörös P, Happe S, Frese A. Axonal polyneuropathy in obstructive sleep apnoea. J Neurol Neurosurg Psychiatry. 2001;70(5):685–7. https://doi.org/10.1136/jnnp.70.5.685.CrossRefPubMedPubMedCentral

68.

Dziewas R, Schilling M, Engel P, et al. Treatment for obstructive sleep apnoea: effect on peripheral nerve function. J Neurol Neurosurg Psychiatry. 2007;78(3):295–7. https://doi.org/10.1136/jnnp.2006.102806.CrossRefPubMed

69.

Schober AK, Neurath MF, Harsch IA. Prevalence of sleep apnoea in diabetic patients. Clin Respir J. 2011;5(3):165–72. https://doi.org/10.1111/j.1752-699X.2010.00216.x.CrossRefPubMed

70.

Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med. 2012;186(5):434–41. https://doi.org/10.1164/rccm.201112-2135OC.CrossRefPubMedPubMedCentral

71.

Fujihara K, Kodama S, Horikawa C, et al. The relationship between diabetic neuropathy and sleep apnea syndrome: a meta-analysis. Sleep Disord. 2013;2013:150371. https://doi.org/10.1155/2013/150371.CrossRefPubMedPubMedCentral

72.

Altaf QA, Ali A, Piya MK, Raymond NT, Tahrani AA. The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes. J Diabetes Complicat. 2016;30(7):1315–20. https://doi.org/10.1016/j.jdiacomp.2016.05.025.CrossRef

73.

Leong WB, Jadhakhan F, Taheri S, Thomas GN, Adab P. The association between obstructive sleep apnea on diabetic kidney disease: a systematic review and meta-analysis. Sleep. 2016;39(2):301–8. https://doi.org/10.5665/sleep.5432.CrossRefPubMedPubMedCentral

74.

Siwasaranond N, Nimitphong H, Manodpitipong A, et al. The relationship between diabetes-related complications and obstructive sleep apnea in type 2 diabetes. J Diabetes Res. 2018;2018:9269170. https://doi.org/10.1155/2018/9269170.CrossRefPubMedPubMedCentral

75.

Tahrani AA, Ali A, Raymond NT, et al. Obstructive sleep apnea and diabetic nephropathy: a cohort study. Diabetes Care. 2013;36(11):3718–25. https://doi.org/10.2337/dc13-0450.CrossRefPubMedPubMedCentral

76.

Tahrani AA, Dubb K, Raymond NT, et al. Cardiac autonomic neuropathy predicts renal function decline in patients with type 2 diabetes: a cohort study. Diabetologia. 2014;57(6):1249–56. https://doi.org/10.1007/s00125-014-3211-2.CrossRefPubMed

77.

Yun JS, Ahn YB, Song KH, et al. The association between abnormal heart rate variability and new onset of chronic kidney disease in patients with type 2 diabetes: a ten-year follow-up study. Diabetes Res Clin Pract. 2015;108(1):31–7. https://doi.org/10.1016/j.diabres.2015.01.031.CrossRefPubMed

78.

Faulx MD, Storfer-Isser A, Kirchner HL, et al. Obstructive sleep apnea is associated with increased urinary albumin excretion. Sleep. 2007;30(7):923–9. https://doi.org/10.1093/sleep/30.7.923.CrossRefPubMedPubMedCentral

79.

Iseki K, Tohyama K, Matsumoto T, Nakamura H. High prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD). Hypertens Res. 2008;31(2):249–55. https://doi.org/10.1291/hypres.31.249.CrossRefPubMed

80.

Kanbay A, Buyukoglan H, Ozdogan N, et al. Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. Int Urol Nephrol. 2012;44(2):535–9. https://doi.org/10.1007/s11255-011-9927-8.CrossRefPubMed

81.

Leong WB, Nolen M, Thomas GN, Adab P, Banerjee D, Taheri S. The impact of hypoxemia on nephropathy in extremely obese patients with type 2 diabetes mellitus. J Clin Sleep Med. 2014;10(7):773–8. https://doi.org/10.5664/jcsm.3870.CrossRefPubMedPubMedCentral

82.

Bulcun E, Ekici M, Ekici A, Cimen DA, Kisa U. Microalbuminuria in obstructive sleep apnea syndrome. Sleep Breath. 2015;19(4):1191–7. https://doi.org/10.1007/s11325-015-1136-8.CrossRefPubMed

83.

Hanly P. Sleep disorders and end-stage renal disease. Curr Opin Pulm Med. 2008;14(6):543–50. https://doi.org/10.1097/MCP.0b013e3283130f96.CrossRefPubMed

84.

Tada T, Kusano KF, Ogawa A, et al. The predictors of central and obstructive sleep apnoea in haemodialysis patients. Nephrol Dial Transplant. 2007;22(4):1190–7. https://doi.org/10.1093/ndt/gfl748.CrossRefPubMed

85.

Hanly P. Sleep apnea and daytime sleepiness in end-stage renal disease. Semin Dial. 2004;17(2):109–14. https://doi.org/10.1111/j.0894-0959.2004.17206.x.CrossRefPubMed

86.

Abuyassin B, Sharma K, Ayas NT, Laher I. Obstructive sleep apnea and kidney disease: a potential bidirectional relationship? J Clin Sleep Med. 2015;11(8):915–24. https://doi.org/10.5664/jcsm.4946.CrossRefPubMedPubMedCentral

87.

Leong WB, Jadhakhan F, Taheri S, Chen YF, Adab P, Thomas GN. Effect of obstructive sleep apnoea on diabetic retinopathy and maculopathy: a systematic review and meta-analysis. Diabet Med. 2016;33(2):158–68. https://doi.org/10.1111/dme.12817.CrossRefPubMed

88.

Zhu Z, Zhang F, Liu Y, et al. Relationship of obstructive sleep apnoea with diabetic retinopathy: a meta-analysis. Biomed Res Int. 2017;2017:4737064. https://doi.org/10.1155/2017/4737064.CrossRefPubMedPubMedCentral

89.

Shiba T, Sato Y, Takahashi M. Relationship between diabetic retinopathy and sleep-disordered breathing. Am J Ophthalmol. 2009;147(6):1017–21. https://doi.org/10.1016/j.ajo.2008.12.027.CrossRefPubMed

90.

Shiba T, Maeno T, Saishin Y, Hori Y, Takahashi M. Nocturnal intermittent serious hypoxia and reoxygenation in proliferative diabetic retinopathy cases. Am J Ophthalmol. 2010;149(6):959–63. https://doi.org/10.1016/j.ajo.2010.01.006.CrossRefPubMed

91.

Verdecchia P, Angeli F, Mazzotta G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension. 2012;60(1):34–42. https://doi.org/10.1161/HYPERTENSIONAHA.112.191858.CrossRefPubMed

92.

Najafi MT, Khaloo P, Alemi H, et al. Ambulatory blood pressure monitoring and diabetes complications: targeting morning blood pressure surge and nocturnal dipping. Medicine (Baltimore). 2018;97(38):e12185. https://doi.org/10.1097/MD.0000000000012185.CrossRef

93.

Altaf QA, Dodson P, Ali A, et al. Obstructive sleep apnea and retinopathy in patients with type 2 diabetes. A longitudinal study. Am J Respir Crit Care Med. 2017;196(7):892–900. https://doi.org/10.1164/rccm.201701-0175OC.CrossRefPubMedPubMedCentral

94.

Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009;373(9657):82–93. https://doi.org/10.1016/S0140-6736(08)61622-0.CrossRefPubMed

95.

Seicean S, Strohl KP, Seicean A, Gibby C, Marwick TH. Sleep disordered breathing as a risk of cardiac events in subjects with diabetes mellitus and normal exercise echocardiographic findings. Am J Cardiol. 2013;111(8):1214–20. https://doi.org/10.1016/j.amjcard.2012.12.053.CrossRefPubMed

96.

Foster GD, Borradaile KE, Sanders MH, Sleep AHEAD Research Group of Look AHEAD Research Group, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619–26. https://doi.org/10.1001/archinternmed.2009.266.CrossRefPubMedPubMedCentral

97.

Look Ahead Research Group, Bray G, Gregg E, Haffner S, et al. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Vasc Dis Res. 2006;3(3):202–15. https://doi.org/10.3132/dvdr.2006.031.CrossRef

98.

Rice TB, Foster GD, Sanders MH, Sleep AHEAD Research Group, et al. The relationship between obstructive sleep apnea and self-reported stroke or coronary heart disease in overweight and obese adults with type 2 diabetes mellitus. Sleep. 2012;35(9):1293–8. https://doi.org/10.5665/sleep.2090.CrossRefPubMedPubMedCentral

99.

Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med. 2005;172(11):1447–51. https://doi.org/10.1164/rccm.200505-702OC.CrossRefPubMedPubMedCentral

100.

Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med. 2010;182(2):269–77. https://doi.org/10.1164/rccm.200911-1746OC.CrossRefPubMedPubMedCentral

101.

Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122(4):352–60. https://doi.org/10.1161/CIRCULATIONAHA.109.901801.CrossRefPubMedPubMedCentral

102.

Shen H, Zhao J, Liu Y, Sun G. Interactions between and shared molecular mechanisms of diabetic peripheral neuropathy and obstructive sleep apnea in type 2 diabetes patients. J Diabetes Res. 2018;2018:3458615. https://doi.org/10.1155/2018/3458615.CrossRefPubMedPubMedCentral

103.

Nannapaneni S, Ramar K, Surani S. Effect of obstructive sleep apnea on type 2 diabetes mellitus: a comprehensive literature review. World J Diabetes. 2013;4(6):238–44. https://doi.org/10.4239/wjd.v4.i6.238.CrossRefPubMedPubMedCentral

104.

Adeshara KA, Diwan AG, Tupe RS. Diabetes and complications: cellular signaling pathways, current understanding and targeted therapies. Curr Drug Targets. 2016;17(11):1309–28. https://doi.org/10.2174/1389450117666151209124007.CrossRefPubMed

105.

Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes. 1995;44(7):824–9. https://doi.org/10.2337/diab.44.7.824.CrossRefPubMed

106.

Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation end products and pathways to the complications of diabetes. Vascul Pharmacol. 2012;57(5–6):160–7. https://doi.org/10.1016/j.vph.2012.06.004.CrossRefPubMedPubMedCentral

107.

Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–52. https://doi.org/10.1042/CS20120198.CrossRef

108.

Xu J, Chen LJ, Yu J, et al. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. Cell Physiol Biochem. 2018;48(2):705–17. https://doi.org/10.1159/000491897.CrossRefPubMed

109.

Lavie L. Oxidative stress inflammation and endothelial dysfunction in obstructive sleep apnea. Front Biosci (Elite Ed). 2012;4:1391–403. https://doi.org/10.2741/469 (PMID: 22201964).CrossRef

110.

Umeno A, Biju V, Yoshida Y. In vivo ROS production and use of oxidative stress-derived biomarkers to detect the onset of diseases such as Alzheimer’s disease, Parkinson’s disease, and diabetes. Free Radic Res. 2017;51(4):413–27. https://doi.org/10.1080/10715762.2017.1315114.CrossRefPubMed

111.

Wang N, Khan SA, Prabhakar NR, Nanduri J. Impairment of pancreatic β-cell function by chronic intermittent hypoxia. Exp Physiol. 2013;98(9):1376–85. https://doi.org/10.1113/expphysiol.2013.072454.CrossRefPubMedPubMedCentral

112.

Fiedorczuk P, Stróżyński A, Olszewska E. Is the oxidative stress in obstructive sleep apnea associated with cardiovascular complications? Systematic review. J Clin Med. 2020;9(11):3734. https://doi.org/10.3390/jcm9113734.CrossRefPubMedCentral

113.

Lavie L. Oxidative stress: a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis. 2009;51(4):303–12. https://doi.org/10.1016/j.pcad.2008.08.003.CrossRefPubMed

114.

Turek NF, Ricardo AC, Lash JP. Sleep disturbances as non traditional risk factors for development and progression of CKD: review of the evidence. Am J Kidney Dis. 2012;60(5):823–33. https://doi.org/10.1053/j.ajkd.2012.04.027.CrossRefPubMedPubMedCentral

115.

Sakaguchi Y, Hatta T, Hayashi T, et al. Association of nocturnal hypoxemia with progression of CKD. Clin J Am Soc Nephrol. 2013;8(9):1502–7. https://doi.org/10.2215/CJN.11931112.CrossRefPubMedPubMedCentral

116.

Nowakowski S, Matthews KA, von Känel R, Hall MH, Thurston RC. Sleep characteristics and inflammatory biomarkers among midlife women. Sleep. 2018;41(5):zsy049. https://doi.org/10.1093/sleep/zsy049.CrossRefPubMedCentral

117.

Nadeem R, Molnar J, Madbouly EM, et al. Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J Clin Sleep Med. 2013;9(10):1003–12. https://doi.org/10.5664/jcsm.3070.CrossRefPubMedPubMedCentral

118.

Kheirandish-Gozal L, Gozal D. Obstructive sleep apnea and inflammation: proof of concept based on two illustrative cytokines. Int J Mol Sci. 2019;20(3):459. https://doi.org/10.3390/ijms20030459.CrossRefPubMedCentral

119.

Barone MT, Menna-Barreto L. Diabetes and sleep: a complex cause-and-effect relationship. Diabetes Res Clin Pract. 2011;91(2):129–37. https://doi.org/10.1016/j.diabres.2010.07.011.CrossRefPubMed

120.

Assar ME, Angulo J, Rodríguez-Mañas L. Diabetes and ageing-induced vascular inflammation. J Physiol. 2016;594(8):2125–46. https://doi.org/10.1113/JP270841.CrossRefPubMed

121.

Cimini FA, Barchetta I, Porzia A, et al. Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. Acta Diabetol. 2017;54(10):961–7. https://doi.org/10.1007/s00592-017-1039-1.CrossRefPubMed

122.

Ning Y, Zhang TS, Wen WW, et al. Effects of continuous positive airway pressure on cardiovascular biomarkers in patients with obstructive sleep apnea: a meta-analysis of randomized controlled trials. Sleep Breath. 2019;23(1):77–86. https://doi.org/10.1007/s11325-018-1662-2.CrossRefPubMed

123.

Xu JX, Cai W, Sun JF, et al. Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea. Sleep Breath. 2015;19(3):827–33. https://doi.org/10.1007/s11325-014-1100-z.CrossRefPubMed

124.

Tan KC, Chow WS, Lam JC, et al. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep. 2006;29(3):329–33. https://doi.org/10.1093/sleep/29.3.329.CrossRefPubMed

125.

Wu X, She W, Niu X, Chen X. Association between serum level of advanced glycation end products and obstructive sleep apnea-hypopnea syndrome: a meta-analysis. J Int Med Res. 2018;46(11):4377–85. https://doi.org/10.1177/0300060518786906.CrossRefPubMedPubMedCentral

126.

Marrone O, Battaglia S, Steiropoulos P, ESADA Study Group, et al. Chronic kidney disease in European patients with obstructive sleep apnea: the ESADA cohort study. J Sleep Res. 2016;25(6):739–45. https://doi.org/10.1111/jsr.12426.CrossRefPubMed

127.

Adams RJ, Appleton SL, Vakulin A, et al. Chronic kidney disease and sleep apnea association of kidney disease with obstructive sleep apnea in a population study of men. Sleep. 2017. https://doi.org/10.1093/sleep/zsw015.CrossRefPubMed

128.

Lee YC, Hung SY, Wang HK, et al. Sleep apnea and the risk of chronic kidney disease: a nationwide population-based cohort study. Sleep. 2015;38:213–21. https://doi.org/10.5665/sleep.4400.CrossRefPubMedPubMedCentral

129.

Chu H, Shih CJ, Ou SM, Chou KT, Lo YH, Chen YT. Association of sleep apnoea with chronic kidney disease in a large cohort from Taiwan. Respirology. 2016;21(4):754–60. https://doi.org/10.1111/resp.12739.CrossRefPubMed

130.

Lin YS, Liu PH, Lin SW, et al. Simple obstructive sleep apnea patients without hypertension or diabetes accelerate kidney dysfunction: a population follow-up cohort study from Taiwan. Sleep Breath. 2017;21:85–91. https://doi.org/10.1007/s11325-016-1376-2.CrossRefPubMed

131.

Dou L, Lan H, Reynolds DJ, et al. Association between obstructive sleep apnea and acute kidney injury in critically ill patients: a propensity-matched study. Nephron. 2017;135(2):137–46. https://doi.org/10.1159/000453367.CrossRefPubMed

132.

Lin CH, Perger E, Lyons OD. Obstructive sleep apnea and chronic kidney disease. Curr Opin Pulm Med. 2018;24(6):549–54. https://doi.org/10.1097/MCP.0000000000000525.CrossRefPubMed

133.

Muraki I, Wada H, Tanigawa T. Sleep apnea and type 2 diabetes. J Diabetes Investig. 2018;9(5):991–7. https://doi.org/10.1111/jdi.12823.CrossRefPubMedPubMedCentral

134.

Zinman B, Wanner C, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

135.

Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925.CrossRefPubMed

136.

McMurray JJV, Solomon SD, Inzucchi SE, DAPA-HF Trial Committees and Investigators, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.CrossRefPubMed

137.

Cosentino F, Cannon CP, Cherney DZI, VERTIS CV Investigators, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142(23):2205–15. https://doi.org/10.1161/CIRCULATIONAHA.120.050255.CrossRefPubMedPubMedCentral

138.

Wiviott SD, Raz I, Bonaca MP, DECLARE–TIMI 58 Investigators, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.CrossRefPubMed

139.

Packer M, Anker SD, Butler J, EMPEROR-Reduced Trial Committees and Investigators, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced Trial. Circulation. 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.051783.CrossRefPubMedPubMedCentral

140.

Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744.CrossRefPubMed

141.

Heerspink HJL, Stefánsson BV, Correa-Rotter R, DAPA-CKD Trial Committees and Investigators, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.CrossRefPubMed

142.

Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019;16(16):2965. https://doi.org/10.3390/ijerph16162965.CrossRefPubMedCentral

143.

Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1):F10–8. https://doi.org/10.1152/ajprenal.2001.280.1.F10.CrossRefPubMed

144.

Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–94. https://doi.org/10.1152/physrev.00055.2009.CrossRefPubMed

145.

Vrhovac I, Balen Eror D, Klessen D, et al. Localizations of Na(+)-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467(9):1881–98. https://doi.org/10.1007/s00424-014-1619-7.CrossRefPubMed

146.

Song P, Onishi A, Koepsell H, Vallon V. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets. 2016;20(9):1109–25. https://doi.org/10.1517/14728222.2016.1168808.CrossRefPubMedPubMedCentral

147.

Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: Functional properties and pharmaceutical potential. J Diabetes Investig. 2020;11(4):770–82. https://doi.org/10.1111/jdi.13255.CrossRefPubMedPubMedCentral

148.

Kaur J, Young BE, Fadel PJ. Sympathetic overactivity in chronic kidney disease: consequences and mechanisms. Int J Mol Sci. 2017;18:E1682. https://doi.org/10.3390/ijms18081682.CrossRefPubMed

149.

Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71(5):471–6. https://doi.org/10.1016/j.jjcc.2017.12.004.CrossRefPubMed

150.

Kosiborod M, Cavender MA, Fu AZ, CVD-REAL Investigators and Study Group, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136(3):249–59. https://doi.org/10.1161/CIRCULATIONAHA.117.029190.CrossRefPubMedPubMedCentral

151.

Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Cardiovasc Diabetol. 2018;17(1):91. https://doi.org/10.1186/s12933-018-0737-5.CrossRefPubMedPubMedCentral

152.

Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75-83. https://doi.org/10.1152/ajpregu.00357.2011.CrossRefPubMed

153.

Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306(2):F194-204. https://doi.org/10.1152/ajprenal.00520.2013.CrossRefPubMed

154.

Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304(2):F156–67. https://doi.org/10.1152/ajprenal.00409.2012.CrossRefPubMed

155.

Schnermann J, Persson AE, Agerup B. Tubuloglomerular feedback. Nonlinear relation between glomerular hydrostatic pressure and loop of henle perfusion rate. J Clin Invest. 1973;52(4):862–9. https://doi.org/10.1172/JCI107250.CrossRefPubMedPubMedCentral

156.

Castrop H. Mediators of tubuloglomerular feedback regulation of glomerular filtration: ATP and adenosine. Acta Physiol (Oxf). 2007;189(1):3–14. https://doi.org/10.1111/j.1748-1716.2006.01610.x.CrossRef

157.

Hansen PB, Hashimoto S, Oppermann M, Huang Y, Briggs JP, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the mouse kidney due to preferential activation of A1 or A2 adenosine receptors. J Pharmacol Exp Ther. 2005;315(3):1150–7. https://doi.org/10.1124/jpet.105.091017.CrossRefPubMed

158.

Rabadi MM, Lee HT. Adenosine receptors and renal ischaemia reperfusion injury. Acta Physiol (Oxf). 2015;213(1):222–31. https://doi.org/10.1111/apha.12402.CrossRef

159.

Carlström M, Wilcox CS, Welch WJ. Adenosine A2A receptor activation attenuates tubuloglomerular feedback responses by stimulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol. 2011;300(2):F457–64. https://doi.org/10.1152/ajprenal.00567.2010.CrossRefPubMed

160.

Lai EY, Patzak A, Steege A, et al. Contribution of adenosine receptors in the control of arteriolar tone and adenosine-angiotensin II interaction. Kidney Int. 2006;70(4):690–8. https://doi.org/10.1038/sj.ki.5001650.CrossRefPubMed

161.

Cherney DZ, Perkins BA, Soleymanlou N, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int. 2014;86(5):1057–8. https://doi.org/10.1038/ki.2014.246.CrossRefPubMed

162.

Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, Nishiyama A. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med. 2017;65(7):1057–61. https://doi.org/10.1136/jim-2017-000445.CrossRefPubMedPubMedCentral

163.

Shin SJ, Chung S, Kim SJ, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS ONE. 2016;11(11):e0165703. https://doi.org/10.1371/journal.pone.0165703.CrossRefPubMedPubMedCentral

164.

Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–44. https://doi.org/10.1016/j.jacbts.2020.02.004.CrossRefPubMedPubMedCentral

165.

Körner A, Eklöf AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes. 1994;43(5):629–33. https://doi.org/10.2337/diab.43.5.629.CrossRefPubMed

166.

Gewin L, Zent R, Pozzi A. Progression of chronic kidney disease: too much cellular talk causes damage. Kidney Int. 2017;91(3):552–60. https://doi.org/10.1016/j.kint.2016.08.025.CrossRefPubMed

167.

Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest. 2011;121(10):3981–90. https://doi.org/10.1172/JCI57301.CrossRefPubMedPubMedCentral

168.

Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001;24(3):495–9. https://doi.org/10.2337/diacare.24.3.495.CrossRefPubMed

169.

Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985–7. https://doi.org/10.1161/CIRCULATIONAHA.118.038881.CrossRefPubMed

170.

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62. https://doi.org/10.1111/dom.12127.CrossRefPubMed

171.

Ferrannini E, Baldi S, Frascerra S, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40(6):771–6. https://doi.org/10.2337/dc16-2724.CrossRefPubMed

172.

Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31. https://doi.org/10.1210/jc.2011-2260.CrossRefPubMed

173.

Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159–69. https://doi.org/10.1111/dom.12189.CrossRefPubMed

174.

Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–50. https://doi.org/10.1016/S0140-6736(13)60683-2.CrossRefPubMed

175.

Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;15(727):66–74. https://doi.org/10.1016/j.ejphar.2014.01.040.CrossRef

176.

Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS ONE. 2012;7(2):e30555. https://doi.org/10.1371/journal.pone.0030555.CrossRefPubMedPubMedCentral

177.

Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66–74. https://doi.org/10.1016/j.ejphar.2014.01.040.CrossRefPubMed

178.

Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014;4:e125. https://doi.org/10.1038/nutd.2014.20.CrossRefPubMedPubMedCentral

179.

Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499–508. https://doi.org/10.1172/JCI72227.CrossRefPubMedPubMedCentral

180.

Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract. 2018;4(5):477–82. https://doi.org/10.1002/osp4.294.CrossRefPubMedPubMedCentral

181.

Raj H, Durgia H, Palui R, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review. World J Diabetes. 2019;10(2):114–32. https://doi.org/10.4239/wjd.v10.i2.114.CrossRefPubMedPubMedCentral

182.

Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY. Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease. Endocrinol Metab (Seoul). 2018;33(3):387–94. https://doi.org/10.3803/EnM.2018.33.3.387.CrossRef

183.

Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92. https://doi.org/10.1111/dom.13520.CrossRefPubMed

184.

Omori K, Nakamura A, Miyoshi H, et al. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. Metabolism. 2019;98:27–36. https://doi.org/10.1016/j.metabol.2019.06.006.CrossRefPubMed

185.

Yagi S, Hirata Y, Ise T, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;4(9):78. https://doi.org/10.1186/s13098-017-0275-4.CrossRef

186.

Shimabukuro M, Hirata Y, Tabata M, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33(5):1077–84. https://doi.org/10.1161/ATVBAHA.112.300829.CrossRefPubMed

187.

Mahabadi AA, Lehmann N, Kälsch H, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis: results from the Heinz Nixdorf recall study. JACC Cardiovasc Imaging. 2014;7(9):909–16. https://doi.org/10.1016/j.jcmg.2014.07.002.CrossRefPubMed

188.

Spallone V, Valensi P. SGLT2 inhibitors and the autonomic nervous system in diabetes: a promising challenge to better understand multiple target improvement. Diabetes Metab. 2021;47:101224. https://doi.org/10.1016/j.diabet.2021.101224.CrossRefPubMed

189.

Li N, Li HP, Wang P, Yan YR, Li SQ, Li QY. Nocturnal mean oxygen saturation is associated with secondary polycythemia in young adults with obstructive sleep apnea, especially in men. Nat Sci Sleep. 2019;11:377–86. https://doi.org/10.2147/NSS.S226143.CrossRefPubMedPubMedCentral

190.

Grau M, Cremer JM, Schmeichel S, Kunkel M, Bloch W. Comparisons of blood parameters, red blood cell deformability and circulating nitric oxide between males and females considering hormonal contraception: a longitudinal gender study. Front Physiol. 2018;9:1835. https://doi.org/10.3389/fphys.2018.01835.CrossRefPubMedPubMedCentral

191.

Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41(2):356–63. https://doi.org/10.2337/dc17-1096.CrossRefPubMed

192.

Sawada K, Karashima S, Kometani M, et al. Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes. Endocr J. 2018;65(4):461–7. https://doi.org/10.1507/endocrj.EJ17-0440.CrossRefPubMed

193.

Tang Y, Sun Q, Bai XY, Zhou YF, Zhou QL, Zhang M. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Nutr Diabetes. 2019;9(1):32. https://doi.org/10.1038/s41387-019-0098-5.CrossRefPubMedPubMedCentral

194.

Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5. https://doi.org/10.1093/sleep/14.6.540.CrossRefPubMed

195.

Yoshimoto T, Furuki T, Kobori H, et al. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med. 2017;65(7):1057–61. https://doi.org/10.1136/jim-2017-000445.CrossRefPubMedPubMedCentral

196.

Neeland IJ, Eliasson B, Kasai T, EMPA-REG OUTCOME Investigators, et al. The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020;43(12):3007–15. https://doi.org/10.2337/dc20-1096.CrossRefPubMedPubMedCentral

197.

Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018;20(6):1361–6. https://doi.org/10.1111/dom.13229.CrossRefPubMed

198.

Avogaro A, Fadini GP. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Diabetes Obes Metab. 2018;20(6):1367–8. https://doi.org/10.1111/dom.13234.CrossRefPubMed

199.

Wu P, Wen W, Li J, et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. Horm Metab Res. 2019;51(8):487–94. https://doi.org/10.1055/a-0958-2441.CrossRefPubMed

200.

Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298–309.CrossRefPubMed

Title: Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
Authors: Vincenzo Maria Monda
Francesca Porcellati
Felice Strollo
Alessandro Fucili
Marcello Monesi
Ersilia Satta
Sandro Gentile
Publication date: 01-08-2021
Publisher: Springer Healthcare
Keyword: Diabetes
Published in: Advances in Therapy / Issue 8/2021
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-021-01791-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2021

Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care

Factors for Timely Identification of Possible Occurrence of Delirium in Palliative Care: A Prospective Observational Study

Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY

Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service

Correction to: Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis

The Impact of Intravenous Iron Supplementation on Hematinic Parameters and Erythropoietin Requirements in Hemodialysis Patients

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage